Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...
Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...
Shares of Novavax (NASDAQ:NVAX) rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from ...
Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...
The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NYSE: NVO) has come down ...
A group representing compounding pharmacies has filed a lawsuit against the US Food and Drug Administration, arguing that the ...
GLP-1 Receptor Agonist Market. The global GLP-1 receptor agonist market is on the verge of unprecedented growth, fueled by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results